# Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

> **NCT05551858** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Georgetown University** · enrollment: 32 (estimated)

## Conditions studied

- Safety Issues
- Pain
- Pancreas Fibrosis

## Interventions

- **DRUG:** Proglumide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05551858
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-17
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551858, "Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05551858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*